rosiglitazone has been researched along with ertiprotafib in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bhattarai, BR; Cho, H; Ham, SW; Han, IO; Hwang, JS; Kafle, B; Kang, JS; Khadka, D; Lee, SM; Park, H | 1 |
| Azukizawa, S; Fukui, M; Kamemoto, H; Kanda, M; Kasai, M; Kunishiro, K; Miike, T; Otake, K; Shirahase, H | 1 |
2 other study(ies) available for rosiglitazone and ertiprotafib
| Article | Year |
|---|---|
Thiazolidinedione derivatives as PTP1B inhibitors with antihyperglycemic and antiobesity effects.
Topics: Animals; Anti-Obesity Agents; Binding Sites; Blood Glucose; Catalytic Domain; Computer Simulation; Enzyme Inhibitors; Hypoglycemic Agents; Mice; Phenyl Ethers; PPAR gamma; Protein Tyrosine Phosphatase, Non-Receptor Type 1; Thiazolidinediones | 2009 |
Novel (S)-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acids: peroxisome proliferator-activated receptor γ selective agonists with protein-tyrosine phosphatase 1B inhibition.
Topics: Administration, Oral; Animals; Enzyme Activation; Female; Humans; Hypoglycemic Agents; Isoquinolines; Male; Mice; Oxazoles; PPAR gamma; Protein Tyrosine Phosphatase, Non-Receptor Type 1; Rats; Rats, Sprague-Dawley; Stereoisomerism; Structure-Activity Relationship; Tetrahydroisoquinolines | 2012 |